| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Service de Médecine Nucléaire et de Cancérologie Endocrinienne (G.As., S.L., J.-P.T., C.D., M.S., E.B.), Département de Santé Publique (G.An.) and Département d’Anatomo-Pathologie (B.C.), Institut Gustave-Roussy, Université Paris XI, 94800 Villejuif, France; Département d’Anatomo-Pathologie (F.T.) and Service d’Endocrinologie (G.Ab., X.B., J.B.), Hôpital Cochin, Université Paris V René Descartes, Faculté de Médécine, Site Cochin-Port-Royal, 75014 Paris, France; Département Endocrinologie-Métabolisme-Cancer (F.T., X.B., J.B.), Institut National de la Santé et de la Recherche Médicale U567 and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut Cochin, 75014 Paris, France; and Laboratoire d’Explorations Fonctionnelles Endocriniennes (C.G.), Institut National de la Santé et de la Recherche Médicale U-515, Hôpital Armand Trousseau, Université Paris VI, 75012 Paris, France
Address all correspondence and requests for reprints to: E. Baudin, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. E-mail: baudin{at}igr.fr.
Context: Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized.
Objective: The objective of the study was to describe the clinical presentation of metastatic ACC and determine prognostic factors for survival.
Design: This was a retrospective cohort study (1988–2004).
Setting: The study was conducted in an institutional practice.
Patients: Participants included 124 consecutive patients with metastatic ACC, 70 from Gustave-Roussy Institute (main cohort) and 54 patients from the Cochin Hospital (validation cohort). Clinical data concerning all patients, histopathologic slides of primary tumors (44 in the main cohort and 40 in the validation cohort), and molecular biology data on 15 primary tumors (main cohort) were analyzed.
Intervention: There was no intervention.
Main Outcome: The main outcome was the specific survival after discovery of the first metastasis (Kaplan-Meier method). This included univariate analysis on the main cohort, confirmed on the validation cohort and then analyzed in a multivariate analysis.
Results: In the main cohort, overall median survival was 20 months. In univariate analysis, the presence of hepatic and bone metastases, the number of metastatic lesions and the number of tumoral organs at the time of the first metastasis, a high mitotic rate (>20 per 50 high-power field), and atypical mitoses in the primary tumor predicted survival (P = 0.05, 0.003, 0.046, 0.001, 0.01, and < 0.001, respectively). The number of tumoral organs and a high mitotic rate were confirmed on the validation cohort (P = 0.009 and 0.03, respectively). These two parameters were confirmed in multivariate analysis (P = 0.0058 and 0.049).
Conclusion: Metastatic ACC is a heterogeneous disease with poor outcome. The combination of the number of tumoral organs at the time of the first metastasis and the mitotic rate can predict different outcomes.
This article has been cited by other articles:
 |
|
 |
|
  I. Veytsman, L. Nieman, and T. Fojo Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma J. Clin. Oncol., September 20, 2009; 27(27): 4619 - 4629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Ronchi, S. Sbiera, L. Kraus, S. Wortmann, S. Johanssen, P. Adam, H. S Willenberg, S. Hahner, B. Allolio, and M. Fassnacht Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy Endocr. Relat. Cancer, September 1, 2009; 16(3): 907 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Fenske, H.-U. Volker, P. Adam, S. Hahner, S. Johanssen, S. Wortmann, M. Schmidt, M. Morcos, H.-K. Muller-Hermelink, B. Allolio, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma Endocr. Relat. Cancer, September 1, 2009; 16(3): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. de Reynies, G. Assie, D. S. Rickman, F. Tissier, L. Groussin, F. Rene-Corail, B. Dousset, X. Bertagna, E. Clauser, and J. Bertherat Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival J. Clin. Oncol., March 1, 2009; 27(7): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Giordano, R. Kuick, T. Else, P. G. Gauger, M. Vinco, J. Bauersfeld, D. Sanders, D. G. Thomas, G. Doherty, and G. Hammer Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling Clin. Cancer Res., January 15, 2009; 15(2): 668 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Volante, C Buttigliero, E Greco, A Berruti, and M Papotti Pathological and molecular features of adrenocortical carcinoma: an update J. Clin. Pathol., July 1, 2008; 61(7): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
